Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma

被引:2
|
作者
Matsumoto, Jun [1 ]
Kotera, Yumi [1 ]
Watari, Shogo [2 ]
Takeuchi, Koichi [1 ]
Ueki, Hideo [2 ]
Koyama, Toshihiro [3 ]
Wada, Koichiro [2 ]
Fujiyoshi, Masachika [1 ]
Nasu, Yasutomo [2 ]
Ariyoshi, Noritaka [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Personalized Med & Prevent Healthcare Sci, Okayama, Japan
[2] Okayama Univ, Grad Sch Med Dent Pharmaceut Sci, Dept Urol, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmaceut Biomed, Okayama, Japan
关键词
human; cytochrome P450 CYP3A; renal cell carcinoma treatment outcome; CYTOCHROME-P450; 3A; OVARIAN-CANCER; IDENTIFICATION; RESISTANCE; ISOFORM; LIVER; RAT;
D O I
10.21873/anticanres.15029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.
引用
收藏
页码:2511 / 2521
页数:11
相关论文
共 50 条
  • [21] Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
    Qu, Lihui
    Lu, Yingying
    Ying, Meike
    Li, Bingjue
    Weng, Chunhua
    Xie, Zhoutao
    Liang, Ludan
    Lin, Chuan
    Yang, Xian
    Feng, Shi
    Wang, Yucheng
    Shen, Xiujin
    Zhou, Qin
    Chen, Ying
    Chen, Zhimin
    Wu, Jianyong
    Lin, Weiqiang
    Shen, Yi
    Qin, Jing
    Xu, Hang
    Xu, Feng
    Wang, Junwen
    Chen, Jianghua
    Jiang, Hong
    Huang, Hongfeng
    ONCOTARGET, 2017, 8 (46) : 81285 - 81294
  • [22] Selective expression of CYP3A5 and not CYP3A4 in human blood
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Thummel, KE
    Watkins, PB
    PHARMACOGENETICS, 1996, 6 (05): : 379 - 385
  • [23] Expression and localization of CYP3A4 and CYP3A5 in human lung
    Anttila, S
    Hukkanen, J
    Hakkola, J
    Stjernvall, T
    Beaune, P
    Edwards, RJ
    Boobis, AR
    Pelkonen, O
    Raunio, H
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (03) : 242 - 249
  • [24] The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients
    Yates, CR
    Zhang, WH
    Song, PF
    Li, S
    Gaber, AO
    Kotb, M
    Honaker, MR
    Alloway, RR
    Meibohm, B
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (06): : 555 - 564
  • [25] p53 expression in correlation to clinical outcome in patients with renal cell carcinoma
    Ljungberg, B
    Bozoky, B
    Kovacs, G
    Stattin, P
    Farrelly, E
    Nylander, K
    Landberg, G
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2001, 35 (01): : 15 - 20
  • [26] A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
    Lee, Su-Jun
    van der Heiden, Ilse P.
    Goldstein, Joyce A.
    van Schaik, Ron H. N.
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (01) : 67 - 71
  • [27] The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma
    Dingqi Sun
    Jiaju Lu
    Kejia Ding
    Dongbin Bi
    Zhihong Niu
    Qingwei Cao
    Jie Zhang
    Sentai Ding
    Medical Oncology, 2013, 30
  • [28] The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma
    Sun, Dingqi
    Lu, Jiaju
    Ding, Kejia
    Bi, Dongbin
    Niu, Zhihong
    Cao, Qingwei
    Zhang, Jie
    Ding, Sentai
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [29] Effects of CYP3A4*22 carrier and CYP3A5 expressor status on clinical outcome in patients treated with ticagrelor for acute coronary syndrome
    Azzahhafi, J.
    Bergmeijer, T. O.
    Van Den Broek, W. W. A.
    Yin, D. R. P. P. Chan Pin
    Rayhi, S.
    Peper, J.
    Bor, Wi.
    Van Schaik, R. H. N.
    Ten Berg, J. M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1230 - 1230
  • [30] Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma
    Azarpira, Negar
    Ashraf, Mohamad Javad
    Khademi, Bigan
    Darai, Masumeh
    Hakimzadeh, Afsoon
    Abedi, Elham
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (08) : 5443 - 5448